2. Metabolic Disease

Metabolic Disease

Metabolic Disease

Related Products

PDF 53.7 MB

Metabolic diseases is defined by a constellation of interconnected physiological, biochemical, clinical, and metabolic factors that directly increases the risk of cardiovascular disease, type 2 diabetes mellitus, and all cause mortality. Associated conditions include hyperuricemia, fatty liver (especially in concurrent obesity) progressing to nonalcoholic fatty liver disease, polycystic ovarian syndrome (in women), erectile dysfunction (in men), and acanthosis nigricans. Metabolic disease modeling is an essential component of biomedical research and a mandatory prerequisite for the treatment of human disease. Somatic genome editing using CRISPR/Cas9 might be used to establish novel metabolic disease models.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-W016750R
    Pentane-1,5-diamine dihydrochloride (Standard) 1476-39-7 99.97%
    Pentane-1,5-diamine dihydrochloride is an endogenous metabolite.
    Pentane-1,5-diamine dihydrochloride (Standard)
  • HY-W017522S
    Adipic acid-d10 25373-21-1 99.93%
    Adipic acid-d10 (Hexanedioic acid-d10) is the deuterium labeled Adipic acid (HY-W017522). Adipic acid (Hexanedioic acid) is an orally active compound with anti-HSV-1 activity. Adipic acid has low toxicity and can be used as a food additive and a gelling agent. Adipic acid can also be used in the synthesis of lubricants, artificial resins, plastics, etc.
    Adipic acid-d10
  • HY-W018004S
    L-Homocitrulline-d3 99.68%
    L-Homocitrulline-d3 is the deuterium labeled L-Homocitrulline. L-Homocitrulline is metabolized to homoarginine through homoargininosuccinate via the urea cycle pathway and its metabolic abnormality could lead to Lysinuric Protein Intolerance (LPI).
    L-Homocitrulline-d3
  • HY-W010489S2
    2-Phenylacetaldehyde-d5 879549-73-2
    2-Phenylacetaldehyde-d5 is deuterated labeled 2-Phenylacetaldehyde (HY-W010489). 2-Phenylacetaldehyde is an endogenous metabolite.
    2-Phenylacetaldehyde-d5
  • HY-W012980S2
    Isovaleric acid-d2 95927-02-9 99.49%
    Isovaleric acid-d2 is the deuterium labeled Isovaleric acid. Isovaleric acid is a natural fatty acid and known to effect on neonatal death and possible Jamaican vomiting sickness in human.
    Isovaleric acid-d2
  • HY-128145
    HSD17B13-IN-41 1122660-25-6
    HSD17B13-IN-41 (Compound C) is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13). HSD17B13-IN-41 can be used for research on liver diseases, metabolic diseases, or cardiovascular diseases, such as NAFLD or NASH.
    HSD17B13-IN-41
  • HY-10195A
    Ruboxistaurin mesylate 192050-59-2 99.87%
    Ruboxistaurin (LY333531) mesylate is an orally active, selective and ATP competitive PKCβ inhibitor with IC50 values of 4.7 and 5.9 nM for PKCβI and PKCβII, respectively. Ruboxistaurin mesylate can be used for the research of eye disorders, heart failure and diabetes.
    Ruboxistaurin mesylate
  • HY-19908B
    (R)-BAY-85-8501 2446175-39-7 99.09%
    (R)-BAY-85-8501 is the less active Enantiomer of BAY-85-8501. BAY-85-8501 is a selective and potent inhibitor of Human Neutrophil Elastase (HNE), with an IC50 of 65 pM.
    (R)-BAY-85-8501
  • HY-B0589E
    Atorvastatin hemicalcium trihydrate 344920-08-7 99.70%
    Atorvastatin hemicalcium trihydrate is an orally active HMG-CoA reductase inhibitor, has the ability to effectively decrease blood lipids. Atorvastatin hemicalcium trihydrate inhibits human SV-SMC proliferation and invasion with IC50s of 0.39 μM and 2.39 μM, respectively.
    Atorvastatin hemicalcium trihydrate
  • HY-12648
    FASN-IN-4 1375105-96-6 99.21%
    FASN-IN-4 is a potent inhibitor of fatty acid synthase (FASN) with an IC50 of 10 nM (WO2012064642A1, compound 29). FASN-IN-4 also inhibits SARS-CoV-2 with an EC50 of 18.6 nM.
    FASN-IN-4
  • HY-12981
    RG7713 920022-47-5 99.92%
    RG7713 (RO5028442) is a highly potent, selective and brain-penetrant Vasopressin 1a (V1a) receptor antagonist with Kis of 1 nM (hV1a) and 39 nM (mV1a).
    RG7713
  • HY-13414
    Remogliflozin 329045-45-6 99.5%
    Remogliflozin (Remogliflozin A) is an orally active, highly selective sodium-glucose cotransporter 2 (SGLT2) inhibitor, with a Ki of 12.4 nM for human SGLT2 and 26.0 nM for rat SGLT2. Remogliflozin increases urinary glucose excretion by inhibiting renal glucose reabsorption. Without insulin stimulation, remogliflozin suppresses the elevation of plasma glucose, reduces fasting blood glucose and glycated hemoglobin, and improves glycosuria, hyperglycemia, hyperinsulinemia, hypertriglyceridemia and insulin resistance in diabetic rodents. Remogliflozin can be used in research related to type 2 diabetes.
    Remogliflozin
  • HY-14892
    Gemigliptin 911637-19-9 98%
    Gemigliptin (LC15-0444 ) is a highly selective, reversible and competitive dipeptidyl peptidase-4 (DPP-4) inhibitor, with an IC50 of 10.3 nM for human recombinant DPP-4. Gemigliptin exhibits potent anti-glycation properties. Gemigliptin can be used for the research of advanced glycation end products (AGE)-related diabetic complications.
    Gemigliptin
  • HY-B0681
    Acamprosate 77337-76-9 99.34%
    Acamprosate is an orally active prototypic neuromodulator. Acamprosate can be used for the research of alcohol dependence and alcoholism.
    Acamprosate
  • HY-100221
    AM-2394 1442684-77-6 99.30%
    AM-2394 is a structurally distinct glucokinase activator (GKA). AM-2394 activates glucokinase (GK) with an EC50 of 60 nM.
    AM-2394
  • HY-101782
    HSK0935 1638851-44-1
    HSK0935 is a potent, highly selective and orally available SGLT2 inhibitor with an IC50 of 1.3 nM. Antihyperglycemic activities.
    HSK0935
  • HY-101930
    BMS-816336 1009583-20-3 99.86%
    BMS-816336 is a novel, potent and orally bioavailable inhibitor against human 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) enzyme with an IC50 of 3.0 nM.
    BMS-816336
  • HY-105074
    Farglitazar 196808-45-4 99.50%
    Farglitazar is a PPARγ agonist that has significant therapeutic benefits such as glycemic control in type 2 diabetic patients.
    Farglitazar
  • HY-105191
    Azalanstat 143393-27-5 99.52%
    Azalanstat (RS-21607) is an inhibitor of heme oxygenase and lanosterol 14α-demethylase, with inhibitory activity against HO-1 (IC50 = 5.5 µM) and HO-2 (IC50 = 24.5 µM). Azalanstat reduces the maturation rate of rat oocytes, increases rat oocyte degeneration, and partially inhibits progesterone production in preovulatory follicles of rats.
    Azalanstat
  • HY-107773
    GSK3004774 2138814-32-9 99.09%
    GSK3004774 is a potent, nonabsorbable agonist of CaSR, with an pEC50 of 7.3, 6.6 and 6.5 for human, mouse and rat CaSR, respectively. GSK3004774 shows an EC50 of 50 nM for human CaSR.
    GSK3004774
Cat. No. Product Name / Synonyms Application Reactivity